FDA Inspection
Invitrx Therapeutics Inc.Invitrx Therapeutics Inc. – FDA Inspection, Apr 30, 2025
Record Details
This FDA Inspection record concerns Invitrx Therapeutics Inc., with an inspection on April 30, 2025, issued by the Los Angeles District Office, covering biologics.
View Company Profile
ID · 08b1cfe9-b127-4584-818e-f5554d7b3a3d
Inspection Facts
- Inspection number
- 1265382
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
FDA Citations
9- 21 CFR 1271.160(a)All core requirements covered in program
- 21 CFR 1271.180(a)Procedures to meet core CTGP
- 21 CFR 1271.200(a)Cleaned, sanitized per established schedules
- 21 CFR 1271.260(a)Contamination, mix ups, improper release
- 21 CFR 1271.265(c)(1)Release of HCT/Ps by responsible person
- 21 CFR 1271.270(b)Organized to facilitate review
- 21 CFR 1271.290(e)Documenting disposition of each HCT/P
- 21 CFR 1271.50(a)Determination based on screening and testing
- 21 CFR 1271.75(a)(1)Risk factors, clinical evidence
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Invitrx Therapeutics Inc.
3| Date | Classification | Office | Project area |
|---|---|---|---|
| March 22, 2022 | OAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| September 13, 2019 | VAI | Center for Food Safety and Applied Nutrition | Colors and Cosmetics Technology |
| April 3, 2019 | OAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Invitrx Therapeutics Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.